We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+9.46%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$11.9B
AUM Growth
+$1.4B
(+13%)
Cap. Flow
+$748M
Cap. Flow
% of AUM
6.3%
Top 10 Holdings %
Top 10 Hldgs %
12.11%
Holding
747
New
202
Increased
220
Reduced
153
Closed
161
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ASML
ASML
|
+$134M |
| 2 |
STMicroelectronics
STM
|
+$103M |
| 3 |
Meta Platforms (Facebook)
META
|
+$89.9M |
| 4 |
MetLife
MET
|
+$71.9M |
| 5 |
Gilead Sciences
GILD
|
+$70.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TE Connectivity
TEL
|
+$161M |
| 2 |
Eli Lilly
LLY
|
+$153M |
| 3 |
MRSH
Marsh
MRSH
|
+$123M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$91.8M |
| 5 |
Electronic Arts
EA
|
+$79.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 43.43% |
| 2 | Technology | 17.4% |
| 3 | Industrials | 8.07% |
| 4 | Energy | 6.4% |
| 5 | Financials | 6.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
401
Recursion Pharmaceuticals
RXRX
$1.69B
| $4.42M | 0.04% |
671,319
+6,869
| +1% | +$49.2K |
|
402
NVIDIA
NVDA
$5.31T
| $4.39M | 0.04% |
36,163
-107,390
| -75% | -$12.7M |
|
|
ARTV
403
Artiva Biotherapeutics
ARTV
$563M
| $4.37M | 0.04% |
+283,124
| New | +$3.28M |
|
404
LGI Homes
LGIH
$1.36B
| $4.21M | 0.04% |
+35,524
| New | +$3.75M |
|
405
Kulicke & Soffa
KLIC
$4.74B
| $4.19M | 0.04% |
92,901
+28,284
| +44% | +$1.25M |
|
406
iShares US Real Estate ETF
IYR
$4.62B
| $4.19M | 0.04% |
+41,086
| New | +$3.96M |
|
407
Liquidia Corp
LQDA
$7.94B
| $4.15M | 0.03% |
+414,892
| New | +$4.53M |
|
|
RVNC
408
DELISTED
Revance Therapeutics, Inc.
RVNC
| $4.14M | 0.03% |
+797,953
| New | +$3.97M |
|
409
Birkenstock
BIRK
$6.81B
| $4.1M | 0.03% |
83,238
+374
| +0.5% | +$20.3K |
|
|
TRML
410
DELISTED
Tourmaline Bio
TRML
| $4.09M | 0.03% |
159,154
+1,207
| +0.8% | +$20.1K |
|
411
Aquestive Therapeutics
AQST
$481M
| $4.06M | 0.03% |
816,252
+215,293
| +36% | +$838K |
|
412
Neumora Therapeutics
NMRA
$302M
| $4.06M | 0.03% |
307,558
+143,398
| +87% | +$1.67M |
|
413
Honeywell
HON
$76.8B
| $4.06M | 0.03% |
+20,847
| New | +$4.04M |
|
414
JD.com
JD
$43.8B
| $4.06M | 0.03% |
+101,482
| New | +$2.79M |
|
415
Viking Therapeutics
VKTX
$3.88B
| $4.04M | 0.03% |
63,819
-1,607
| -2% | -$94.3K |
|
416
Clorox
CLX
$12.8B
| $3.96M | 0.03% |
24,338
+6,734
| +38% | +$998K |
|
417
Zentalis Pharmaceuticals
ZNTL
$359M
| $3.88M | 0.03% |
1,055,282
-461,795
| -30% | -$1.68M |
|
418
UroGen Pharma
URGN
$2.26B
| $3.88M | 0.03% |
305,642
+1,902
| +0.6% | +$28.2K |
|
|
RAPP
419
Rapport Therapeutics
RAPP
$2.12B
| $3.82M | 0.03% |
186,560
+15,460
| +9% | +$332K |
|
|
ONC
420
BeOne Medicines Ltd
ONC
$36.3B
| $3.78M | 0.03% |
16,848
-28,230
| -63% | -$5.08M |
|
421
VSE Corp
VSEC
$6.32B
| $3.75M | 0.03% |
45,388
+3,240
| +8% | +$282K |
|
422
Lumentum
LITE
$67.6B
| $3.74M | 0.03% |
59,044
-298,496
| -83% | -$16.2M |
|
423
RingCentral
RNG
$5.13B
| $3.74M | 0.03% |
118,157
-10,358
| -8% | -$327K |
|
424
Warby Parker
WRBY
$3.17B
| $3.72M | 0.03% |
+227,645
| New | +$3.43M |
|
425
Wave Life Sciences
WVE
$1.19B
| $3.7M | 0.03% |
+451,813
| New | +$2.7M |
|
Similar funds
PAM
TCIIS
UIM
VAI
Woodline Partners's Q3 2024 Portfolio in Review
As of Q3 2024, Woodline Partners held 747 positions worth $11.9B, up 13% from $10.5B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Woodline Partners deployed $748M of net new capital in Q3 2024, opening 202 new positions and adding to 220 existing holdings. Its largest new stake was ASML: 149,876 shares worth $125M.
By sector, the portfolio is most concentrated in Healthcare at 43% of assets, up from 42% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Eli Lilly, an estimated $153M trimmed.
- Woodline Partners's largest Q3 2024 buy was ASML: 149,876 shares worth $125M.
- Woodline Partners added most to STMicroelectronics in Q3 2024, an estimated $103M increase.
- Woodline Partners's biggest Q3 2024 reduction was Eli Lilly, cutting an estimated $153M.
- Woodline Partners fully exited TE Connectivity in Q3 2024, selling an estimated $161M.
- Woodline Partners's ten largest holdings make up 12% of its $11.9B portfolio in Q3 2024.
- Woodline Partners opened 202 new positions and closed 161 in Q3 2024.
- Woodline Partners's portfolio value rose 13% quarter-over-quarter to $11.9B.
Based on Woodline Partners's 13F filing for Q3 2024, filed 14 Nov 2024.